Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5426-5431

  Howard, Susan J ^a   Lass Flörl, Cornelia ^b   Cuenca Estrella, Manuel ^c   Gomez Lopez, Alicia ^c   Arendrup, Maiken C ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ISAVUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG DETERMINATION; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING METHOD; FUNGUS ISOLATION; FUNGUS MUTANT; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS, INVASIVE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, FUNGAL; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NITRILES; PYRIDINES; TRIAZOLES;

EID: 84885906160     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01111-13     Document Type: Article

References (22)

1. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
2. Krishna G, Moton A, Maiken L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
3. Krishna G, Maiken L, Martinho M, O'Mara E. 2012. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196-4201.
4. Thompson GR, III, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS. 2009. Posaconazole therapeutic drug monitoring: A reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
5. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
6. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
7. Livermore J, Hope W. 2012. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 8:759-765.
8. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. 2011. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn. Microbiol. Infect. Dis. 71:370-377.
9. Seifert H, Aurbach U, Stefanik D, Cornely O. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821.
10. Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF. 2011. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 54:e583-e589. doi:10.1111/j.1439-0507.2010.01996.x.
11. Perkhofer S, Lechner L, Lass-Florl C. 2009. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:1645-1647.
12. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. 2013. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J. Clin. Microbiol. 51:2608-2616.
13. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Florl C, Martin-Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J. 2013. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob. Agents Chemother. 57:3823-3828.
14. de Hoog GS, Guarro J, Gené J, Figueras MJ. 2000. Atlas of clinical fungi. CBS Fungal Biodiversity Centre, Utrecht, The Netherlands.
15. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. doi:10.1111/j.1469-0691.2012.03880.x.
16. Rodriquez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning D, Fegeler W, Gaustad P, Lass-Flörl C, Moore C, Richardson M, Schmalreck A, Velegraki JA, Verweij P. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
17. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin. Microbiol. Infect. 18:E248-E250. doi:10.1111/j.1469 -0691.2012.03890.x.
18. Hope WW, Cuenca-Estrella M, Lass-Florl C, Arendrup MC. 2013. EUCAST technical note on voriconazole and Aspergillus spp. Clin. Microbiol. Infect. 19:E278-E280. doi:10.1111/1469-0691.12148.
19. Warn PA, Sharp A, Denning DW. 2006. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57:135-138.
20. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52: 1396-1400.
21. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: Epidemiology and detection. Med. Mycol. 49(Suppl 1):S90-S95. doi:10.3109/13693786.2010.508469.
22. Arendrup MC, Garcia-Effron G, Buzina W, Mortensen KL, Reiter N, Lundin C, Jensen HE, Lass-Florl C, Perlin DS, Bruun B. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: Laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.